HKeyBio Launches NHP Fast-Tox Program for Accelerating Non-GLP NHP Safety Risk Screening

▤ Summary

HKeyBio launched its NHP Fast-Tox Program to help biotech teams screen non-human primate safety risks earlier in drug development. The service focuses on early tolerability, PK/TK-linked safety evaluation, immune-risk screening, and pre-GLP dose design for biologics and immunomodulatory programs. It targets candidates such as antibodies, bispecifics, fusion proteins, ADCs, cell therapies, and other immune-modulating therapeutics. The company positions the program as a way to generate decision-relevant exploratory data before formal IND-enabling toxicology studies. The announcement also highlights a potential commercial opening for teams that need early safety data before financing, partnership discussions, or GLP study planning.

▦ Linked Companies